Evidence map›Paper›PMID 34884180›Full record

ArticleJournal of clinical medicine2021

Multiple Approaches at Admission Based on Lung Ultrasound and Biomarkers Improves Risk Identification in COVID-19 Patients.

Jorge Rubio-Gracia, Marta Sánchez-Marteles, Vanesa Garcés-Horna, Luis Martínez-Lostao, Fernando Ruiz-Laiglesia, Silvia Crespo-Aznarez, Natacha Peña-Fresneda, Borja Gracia-Tello, Alberto Cebollada, Patricia Carrera-Lasfuentes and 2 more

Open access · goldAbstract read
In one paragraph

Article in Journal of clinical medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Jorge Rubio-GraciaInternal Medicine Department, Clinical Hospital "Lozano Blesa", 50009 Zaragoza, Spain.ORCID 0000-0002-4769-7154
Marta Sánchez-MartelesInternal Medicine Department, Clinical Hospital "Lozano Blesa", 50009 Zaragoza, Spain.ORCID 0000-0001-9067-2158
Vanesa Garcés-HornaInternal Medicine Department, Clinical Hospital "Lozano Blesa", 50009 Zaragoza, Spain.
Luis Martínez-LostaoAragon Health Research Institute, 50009 Zaragoza, Spain.
Fernando Ruiz-LaiglesiaInternal Medicine Department, Clinical Hospital "Lozano Blesa", 50009 Zaragoza, Spain.ORCID 0000-0003-0438-8834
Silvia Crespo-AznarezInternal Medicine Department, Clinical Hospital "Lozano Blesa", 50009 Zaragoza, Spain.ORCID 0000-0002-8470-9396
Natacha Peña-FresnedaAragon Health Research Institute, 50009 Zaragoza, Spain.ORCID 0000-0002-0221-2395
Borja Gracia-TelloInternal Medicine Department, Clinical Hospital "Lozano Blesa", 50009 Zaragoza, Spain.
Alberto CebolladaAragon Health Research Institute, 50009 Zaragoza, Spain.
Patricia Carrera-LasfuentesAragon Health Research Institute, 50009 Zaragoza, Spain.
Juan Ignacio Pérez-CalvoInternal Medicine Department, Clinical Hospital "Lozano Blesa", 50009 Zaragoza, Spain.ORCID 0000-0003-2361-9941
Ignacio Giménez-LópezAragon Health Research Institute, 50009 Zaragoza, Spain.ORCID 0000-0002-6043-4869
Hospital Clínico Universitario Lozano Blesa · ESInstituto de Investigación Sanitaria Aragón · ESUniversidad de Zaragoza · ESCentro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRisk stratification of COVID-19 patients is fundamental to improving prognosis and selecting the right treatment. We hypothesized that a combination of lung ultrasound (LUZ-score), biomarkers (sST2), and clinical models (PANDEMYC score) could be useful to improve risk stratification.

methodsThis was a prospective cohort study designed to analyze the prognostic value of lung ultrasound, sST2, and PANDEMYC score in COVID-19 patients. The primary endpoint was in-hospital death and/or admission to the intensive care unit. The total length of hospital stay, increase of oxygen flow, or escalated medical treatment during the first 72 h were secondary endpoints.

resultsa total of 144 patients were included; the mean age was 57.5 ± 12.78 years. The median PANDEMYC score was 243 (52), the median LUZ-score was 21 (10), and the median sST2 was 53.1 ng/mL (30.9). Soluble ST2 showed the best predictive capacity for the primary endpoint (AUC = 0.764 (0.658-0.871);

conclusionsThe PANDEMYC score, lung ultrasound, and sST2 concentrations upon admission for COVID-19 are independent predictors of intra-hospital death and/or the need for admission to the ICU for mechanical ventilation. The combination of these predictive tools improves the predictive power compared to each one separately. The use of decision trees, based on multivariate models, could be useful in clinical practice.

Indexed as

COVID-19lung ultrasoundST-2

Identifiers

PMID34884180
PMCPMC8658110
OpenAlexW3217464366

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.